Clinical research progress of afatinib therapy for lung cancer
10.12092/j.issn.1009-2501.2021.04.017
- Author:
Yiting HUANG
1
;
Aizong SHEN
2
Author Information
1. Pharmacy College, Anhui University of Chinese Medicine
2. The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Sciences and Technology of China
- Publication Type:Journal Article
- Keywords:
Adverse reactions;
Afatinib;
Clinical efficacy;
Drug combination;
Lung cancer
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2021;26(4):474-480
- CountryChina
- Language:Chinese
-
Abstract:
Afatinib, a second-generation oral tyrosine kinase inhibitor (TKI), is suitable for first-line treatment of advanced non-small-cell lung cancer (NSCLC) and second-line treatment of squamous NSCLC. At present, a large number of strong clinical research data has confirmed the efficacy and safety of afatinib. Therefore, this article reviews the mechanism of action, pharmacokinetic clinical efficacy, combination of drugs, adverse reactions and dose adjustment of afatinib in order to provide ideas for individual rational drug use guidance.
